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ABSTRACT INTRODUCTION
The need for novel classes of antifungal drugs has never been more pressing (1). 43 The numbers of patients who are at risk for developing invasive fungal infections with FLU has been pursued as an approach to improving the treatment of cryptococcal 155 meningitis (27) . Therefore, we investigated the killing kinetics of MEF and MEF-156 derivatives combined with FLU against C. neoformans using time-kill analysis. As shown 157 in Fig. 2A , the combination of fungistatic concentrations of MEF with FLU is fungicidal 158 and sterilizes the culture. Similar behavior was observed with MEF-derivatives with all 159 but 13480 showing >2 Log10 reductions in CFU by 24 hours (Fig. 2B) . These data 160 indicate that combinations of MEF-derivatives with FLU may lead to improved efficacy 161 relative to FLU alone for C. neoformans. 162 163 The in vitro toxicity of mefloquine derivatives against human cell lines is similar to 164 mefloquine. 165 Mefloquine is an FDA-approved drug for malaria and its toxicity has been 166 characterized extensively. MEF is more toxic against immortalized human cell lines than 167 it is against primary cell lines (28); however, these data provide a measure of the relative 168 toxicity of new derivatives compared to the clinically used MEF. Therefore, we determined 169 the LD50 for mefloquine and its derivatives against both HepG2 and A549 cells using 170 metabolic activity assays. As shown in Fig. 3A&B , the IC50 for none of the derivatives 171 differed from mefloquine by approximately two-fold. The antifungal activity for the 172 derivatives improved by 8->64-fold. Therefore, the improved antifungal activity for the 173 derivatives cannot be attributed to a general increase in eukaryotic toxicity. Although 174 MEF has relatively poor antifungal activity, it achieves very high tissue concentrations 175 near its MIC against organisms such as Cryptococcus (29). The relatively small changes 176 in toxicity associated with the increased antifungal activity are very encouraging and 177 suggest the scaffold may be amenable to in vivo therapy.
178
Mefloquine and mefloquine derivatives modulate fungal virulence factors. 179 Fungal virulence traits have long been studied for their contribution to disease 180 pathogenesis and, recently, interest in targeting these processes for the development of 181 new therapies has increased (30). Among the C. albicans virulence traits, hyphal 182 morphogenesis has been one of the most extensively studied both in terms of 183 pathogenesis and molecular targeting (31). Indeed, another quinolone anti-malarial, 184 quinacrine, inhibits C. albicans filamentation (32). We, therefore, examined the effect of 185 MEF and its derivatives on C. albicans morphogenesis. 186 To investigate if MEF and the mefloquine derivatives affected C. albicans ability to 187 form hyphae, the C. albicans reference strain SC5314 was exposed to sublethal 188 concentrations of the molecules under conditions that induce filamentation (1% fetal 189 bovine serum in YPD at 37 o C). At concentrations of one-half MIC, MEF and its derivatives 190 all suppress filamentation; almost all treated cells remain in yeast form but are still viable 191 by propidium iodide (PI) staining ( Fig. 4A) . MEF showed dose-dependent inhibition of 192 filamentation ( Fig. 4B) , while the MEF-derivatives all completely inhibited filamentation at 193 ½ MIC ( Fig. 4C) . Taken together with previously published quinacrine data, this indicates 194 that the quinolone class appears to be a general inhibitor of C. albicans filamentation (33).
195
Two of the most important virulence characteristics of C. neoformans are 196 polysaccharide capsule formation and melanization (34, 35) .
The polysaccharide 197 capsule protects is unique among fungi and protects the cells against a variety of stress 198 including host defense (34, 36) . Importantly, C. neoformans strains that are not able to 199 form capsule are avirulent in mouse models (37) . Melanization is also thought to protect 200 cells against oxidative stress such as macrophage generated reactive oxygen species.
201
Recent patient-derived data have shown that treatment outcome correlates with extent of 202 melanin formation (38). Thus, a drug that prevents capsule and melanin formation may 203 be useful as an adjuvant, even if it is not sufficiently active to directly kill C. neoformans.
204
(37).
205
C. neoformans H99 was exposed to sub-inhibitory concentrations of MEF and 206 MEF-derivatives in capsule-inducing conditions and capsule formation was evaluated at 207 48 h by India ink staining. Treated cells were stained with PI before imaging to confirm 208 that they were still viable. All MEF-derivatives caused a reduction in the number of cells 209 with capsule and a decrease in size of capsule compared to DMSO (Fig. 5A&B) . 210 Similarly, the MEF-related compounds reduced melanization of C. neoformans cells 211 incubated on L-DOPA plates ( Fig. 5C ). Taken together, these data indicate that MEF-212 derivatives modulate the expression of key virulence properties of pathogenic fungi and 213 directly kill the organisms.
214
Mode and mechanism of the antifungal activity of the mefloquine scaffold 215 As alluded to in the introduction, the mechanism of action for MEF as an anti-216 malarial drug has remained enigmatic despite its many years of use in the clinical setting.
217
Recent proposals for its mechanism of action either as an antimalarial drug or as part of is not essential and, thus, this target was eliminated from further consideration. We tested 223 the effect of MEF and MEF-derivatives on yeast protein translation but found no evidence 224 of inhibition (data not shown). Soon after we completed these experiments, Sheridan et 225 al. reported that they also did not observed any effect of MEF on malarial cell protein 226 translation (43).
227
MEF was identified as a potential adjuvant therapy for chronic myeloid leukemia 228 and, as part of a multi-disciplinary effort to understand its mechanism on anti-cancer 229 activity, a yeast-based chemical haploinsufficiency screen was performed to identify S. 230 cerevisiae genes deletions that are hyper-susceptible to MEF (39). The set of genes that 231 emerged from this screen was enriched for genes involved in yeast vacuole and protein 232 secretion processes. Follow-up cell biological studies using human cells were consistent 233 with this potential mechanism; however, no experiments involving yeast were reported.
234
To investigate the effect of MEF-derivatives on yeast vacuoles, log phase S. 235 cerevisiae cells (BY4741) were exposed to sub-inhibitory concentrations of compound or 236 DMSO for 2 h, stained with FM4-64, and imaged. All MEF-derivatives caused gross 237 changes in vacuole morphology (Fig. 6) ; similar results were observed with C. albicans 238 (data not shown). The changes begin with segmentation and invagination of a single 239 vacuole and lead to many cells having an increased number of fragmented vacuoles.
240
Many cells showed a single large vacuole surrounded by a varying number of smaller 241 vacuoles that resembled class F vacuolar protein sorting mutants (44), which include 242 VPS1 and VPS26 deletions. To directly compare phenotypes, we stained vps1Δ S. 243 cerevisiae (BY4741 background) alongside DMSO or drug treated cells and indeed many 244 cells showed vacuoles with morphology similar to vps1Δ (Fig. 6B) . 245 Although the morphological effects of the MEF-derivatives were not as uniform as 246 observed with vps1∆, it seemed possible that Vps1 could be a target. Many VPS mutants 247 mis-localize the vacuolar protein, Carboxypeptidase Y (CPY), to the extracellular space.
248
However, we found that exposure of BY4741 to the MEF-derivatives did not lead to 249 increased secretion of CPY by colony blot assays (data not shown). The vps1∆ mutant 250 has a strong CPY secretion phenotype Although this assay is not as sensitive as 251 radiolabeling assays, it seems likely that the MEF-derivatives do not have a profound in pathogenic yeast, log phase C. albicans cells (SC5314) were exposed cells to sub-267 inhibitory concentrations of drug or DMSO for 2 h, stained with MitoTracker Red CMXRos 268 and Green, and imaged. MitoTracker Red uptake is dependent on the mitochondrial 269 membrane potential while Green is not. As shown for 13480, MitoTracker Red uptake 270 was nearly abolished while the morphology of the mitochondria was unchanged ( Fig. 7A) . 271 The proton motive force was also decreased in C. neoformans (Fig. 7B) . Additionally, 272 similar results were obtained for 2450 (4 µg/ml), 4377 (2 µg/ml), 305758 (4 µg/ml), and 273 MEF (64 µg/ml), indicating that these drugs dissipate the mitochondrial proton motive 274 force as part of its antifungal activity ( Fig. 7C) . 275 Two recently identified antifungal small molecules that directly target the activity, we reasoned that the MIC for the MEF-derivatives should be much lower in the 280 presence of glycerol; however, the MICs of the MEF-derivatives were decreased 281 modestly (e.g., 2-fold; data not shown) for some derivatives or were unchanged. In 282 addition, we compared the activity of MEF-derivatives against C. glabrata KK2001 and a 283 respiratory-deficient rho 0 -derivative of KK2001, which has no functioning mitochondrion.
284
The MICs were identical for the parent KK2001 strain and the rho 0 KK2001 strain for 2450 colonies grew on YPG plates while all control colonies showed the expected amount of 300 growth (Fig. 8B) . This observation suggests that MEF-derivatives also affect 301 mitochondrial genome stability.
302
Petite mutants are resistant to FLU, primarily through up-regulation of efflux pumps 303 (49). We, therefore, repeated FIC assays, combining FLU with 4377 in YPD instead of 304 the standard RPMI media to facilitate growth of petite strains; we also carried out the FIC 305 in YPG to suppress the formation of respiratory-deficient strains. In addition, we 306 measured cell density rather than using a visual readout to allow for a more nuanced 307 assessment of the activity of the combinations. Both 4377 and FLU were more modestly 308 more active in YPG as compared to YPD (Fig. 9A) were plated on YPD and incubated at 30 o C. The majority of cells isolated from these 314 plates were morphologically petite ( Fig. 9B) and 20/20 representative petite colonies 315 were unable to grow on glycerol media (data not shown). DAPI staining of the respiratory 316 deficient cells showed decreased mitochondrial DNA staining, confirming these strains 317 had alterations in the DNA content of their mitochondria (Fig. 9C) . Thus, the ability of 318 MEF-derivatives induce petite formation which, in turn, appears to modulate the activity 319 of FLU/MEF analog combinations. Importantly, we did not observe this phenomenon with 320 C. neoformans or C. albicans, most likely because these strains are so-called "petite-321 negative" (data not shown) and cannot grow if their mitochondrial DNA has been lost (50).
322
Taken together, these experiments strongly support the notion that MEF-derivatives 323 interfere with mitochondrial function but, like the vacuolar effects, the mitochondrion is not 324 be the sole target driving antifungal activity. Rather, the activity of MEF and its derivatives 325 is best explained by a combination of effects on the mitochondrial and vacuole.
326

DISCUSSION
327
The small number of drugs and drug classes that can be used to treat invasive, 
375
The recent emergence of drug-resistant and multi-drug resistant fungi has 376 generated well-founded concerns in the face of the limited antifungal repertoire (55).
377
Thus, the activity of the MEF-derivatives against multi-drug resistant C. auris and C. 378 glabrata, two of the most important drug-resistant organisms, is very promising. This 379 feature indicates that the class is not susceptible to the mechanisms of resistance such 380 as increased efflux pump expression that affect azole drugs. These observations also 381 suggest that the mechanism and/or mode of action of the MEF class is distinct from 382 antifungal drugs currently in use. Based on these characteristics, further medicinal 383 chemistry optimization of the antifungal activity appears to be warranted.
384
The ability of MEF and its derivatives to achieve high concentrations in the CNS 385 makes them attractive candidates for use in the treatment of cryptococcal meningitis (52).
386
Currently, the gold standard therapy for cryptococcal meningitis is AmB combined with 5-387 flucytosine. As has been well-documented, this regimen is not available in many 388 resource-limited regions of the world with high burden of cryptococcal meningitis (26).
389
FLU is far less effective because of its fungistatic mode of action but is much easier to 
395
The exact mechanism of action for the anti-malarial activity of MEF has remained 396 ill-defined despite its longstanding use. Although our studies on its mechanism of action 397 as an antifungal have not identified a single protein target, new insights into the cellular 398 effects and mode/mechanism of action have emerged. First, our data are most consistent 399 with the idea that the antifungal activity of MEF and its derivatives is due to effects on 400 more than one target. This conclusion is supported by the fact that we could not isolate 401 stable resistant-mutants by in vitro selection.
402
Second, we propose that at least part of the antifungal activity of the MEF class is 403 due to its ability to interfere with the function the function of both the mitochondria and the 404 vacuole. Other antifungal molecules that appear to more specifically target the 405 mitochondria have been identified; however, these molecules typically show increased data indicating that strains with mutations in vacuolar and secretory proteins are 414 hypersusceptible to MEF. Finally, we also assert that the lack of a defined, specific target 415 explaining the anti-malarial activity of MEF may be because, as with its antifungal activity, 416 it has multiple effects and targets.
417
In summary, the broad-spectrum activity, known and favorable pharmacological 418 properties, and the novel, multi-target mechanism of action strongly support the 419 development and optimization of the antifungal activity of the MEF scaffold. culture of cells that were grown overnight (~16 hr) in YPD liquid media, shaking at 30°C.
431
All drugs were solubilized in DMSO.
432
In vitro antifungal susceptibility. Antifungal susceptibility testing was performed using cultures of S. cerevisiae strain BY4741, or a derivative containing a vps1∆ mutation, were 791 exposed to DMSO or the indicated drug concentrations in YPD at 30 o C for 2 hours. The 792 cells were harvested and stained with FM4-65 to visualize the vacuole and photographed.
793
The vacuolar morphology of treated cultures is similar to the pattern reported for the 794 vps1∆ strain. Propidium iodide straining of the same cultures showed that >95% of cells 795 were viable at the time of processing. 
